Vitamin K1

Jaundice, Obstructive, long-acting anticoagulant rodenticides, Vitamin K Deficiency + 17 more
Treatment
10 FDA approvals
17 Active Studies for Vitamin K1

What is Vitamin K1

PhylloquinoneThe Generic name of this drug
Treatment SummaryVitamin K1, also known as phylloquinone or phytonadione, is a type of fat-soluble vitamin used since 1939. It helps the body form blood clotting factors and is used to treat coagulation disorders caused by a vitamin K deficiency. Vitamin K1 has been approved by the FDA since 1955.
Mephytonis the brand name
image of different drug pills on a surface
Vitamin K1 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mephyton
Phylloquinone
1955
65

Approved as Treatment by the FDA

Phylloquinone, also known as Mephyton, is approved by the FDA for 10 uses including Jaundice, Obstructive and Hypoprothrombinemia .
Jaundice, Obstructive
Used to treat Jaundice, Obstructive in combination with Taurocholic acid
Hypoprothrombinemia
Fistula, Biliary
Used to treat Fistula, Biliary in combination with Taurocholic acid
antibacterial therapy
Biliary Fistula
Used to treat Fistula, Biliary in combination with Taurocholic acid
hemorrhagic disease of the newborn
Hypoprothrombinemias
Jaundice, Obstructive
Used to treat Jaundice, Obstructive in combination with Taurocholic acid
Hemorrhagic Disease of Newborn
Salicylate

Effectiveness

How Vitamin K1 Affects PatientsPhylloquinone is a type of vitamin K that can help treat blood clotting issues caused by a vitamin K deficiency. It stays in the body for a long time, so it only needs to be taken occasionally. Most people can tolerate large doses of this vitamin, but it's important to monitor prothrombin time while taking it and be aware of the risk of allergic reactions when given through a needle.
How Vitamin K1 works in the bodyVitamin K helps the body form blood clots. It does this by attaching carboxylic acid groups to a molecule called glutamate, which helps clotting factors bind to calcium. These clotting factors are released from the liver, restoring normal clotting. Vitamin K may also help protect joints from calcification, increase type two collagen and help with bone density. Researchers are still investigating its effects on arthritis, bone density and artery calcification.

When to interrupt dosage

The dose of Vitamin K1 is contingent upon the diagnosed condition, including Sprue, Vitamin supplementation and Ulcerative Colitis. The magnitude of dosage is subject to the application method itemized in the table below.
Condition
Dosage
Administration
long-acting anticoagulant rodenticides
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Vitamin supplementation
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Ulcerative Colitis
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Biliary Fistula
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Anticoagulant Therapy
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Vitamin supplementation therapy
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
hemorrhagic disease of the newborn
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
vitamin K
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Crohn Disease
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Blood Coagulation Disorders
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Celiac Disease
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Jaundice, Obstructive
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Vitamin K Deficiency
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Hypoprothrombinemias
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Intestinal resection
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Hemorrhagic Disease of Newborn
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Salicylate
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Cystic Fibrosis
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
Celiac Disease
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous
antibacterial therapy
, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL
, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Liquid, Intravenous, Solution - Parenteral, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution - Intravenous, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid - Intravenous, Kit - Oral, Kit, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Liquid - Intramuscular, Solution / drops - Oral, Solution, Emulsion - Intramuscular; Intravenous; Subcutaneous

Warnings

Vitamin K1 Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Phylloquinone may interact with Pulse Frequency
There are 20 known major drug interactions with Vitamin K1.
Common Vitamin K1 Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Phylloquinone.
(S)-Warfarin
Major
The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Phylloquinone.
4-hydroxycoumarin
Major
The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Phylloquinone.
Acenocoumarol
Major
The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Phylloquinone.
Clorindione
Major
The therapeutic efficacy of Clorindione can be decreased when used in combination with Phylloquinone.
Vitamin K1 Toxicity & Overdose RiskTaking too much vitamin K1 can be dangerous, especially when given through an IV. The toxic dose of vitamin K1 for mice is 1170 mg/kg when given intravenously and more than 24180 mg/kg when given orally. If someone overdoses on vitamin K1, they should be treated with supportive care.
image of a doctor in a lab doing drug, clinical research

Vitamin K1 Novel Uses: Which Conditions Have a Clinical Trial Featuring Vitamin K1?

At present, 100 active studies are in progress to evaluate the potential of Vitamin K1 in addressing Crohn Disease, Hemorrhagic Disease of the Newborn and Obstructive Jaundice.
Condition
Clinical Trials
Trial Phases
Ulcerative Colitis
14 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1
Jaundice, Obstructive
0 Actively Recruiting
Blood Coagulation Disorders
0 Actively Recruiting
Cystic Fibrosis
0 Actively Recruiting
Vitamin K Deficiency
0 Actively Recruiting
Vitamin supplementation
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
antibacterial therapy
0 Actively Recruiting
Hemorrhagic Disease of Newborn
0 Actively Recruiting
Celiac Disease
0 Actively Recruiting
Hypoprothrombinemias
0 Actively Recruiting
vitamin K
0 Actively Recruiting
hemorrhagic disease of the newborn
0 Actively Recruiting
Vitamin supplementation therapy
0 Actively Recruiting
long-acting anticoagulant rodenticides
0 Actively Recruiting
Celiac Disease
0 Actively Recruiting
Salicylate
0 Actively Recruiting
Anticoagulant Therapy
2 Actively Recruiting
Phase 4, Not Applicable
Intestinal resection
0 Actively Recruiting
Biliary Fistula
0 Actively Recruiting

Patient Q&A Section about vitamin k1

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which is better to take vitamin K1 or K2?

"Several studies have suggested that vitamin K2 is better than K1 at reducing calcium deposits and lowering your risk of heart disease."

Answered by AI

Is vitamin K1 the same as vitamin K?

"Vitamin K1 is the main form of vitamin K in the diet. It's found in green vegetables and in plant chlorophylls. Vitamin K2 is made by bacteria and is found in food where bacteria are part of the production process."

Answered by AI

What is vitamin K1 and K2 good for?

"There are two types of vitamin K, K1 and K2. Both are important for blood clotting and preventing excessive bruising and bleeding. However, recent research suggests that K2 may offer additional health benefits beyond those of K1."

Answered by AI

What is vitamin K1 used for?

"Vitamin K is essential for blood clotting, bone building, and other important processes. There are two main types of vitamin K: K1 (phytonadione) and K2 (menaquinone). Vitamin K1 is found in green vegetables, while vitamin K2 is commonly available as a supplement."

Answered by AI

Clinical Trials for Vitamin K1

Image of Victoria Hospital - London Health Sciences Centre in London, Canada.

Vitamin D for Inflammatory Bowel Disease

18 - 85
All Sexes
London, Canada
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period? 2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients? 3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period? 4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period? 5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients? 6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients? Participants will: * Take 2000 IU of Vitamin D every day for the next 12 months * Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up
Phase 1
Waitlist Available
Victoria Hospital - London Health Sciences CentreTerry Ponich, MD
Image of Rubix LS in Lawrence, United States.

Mirikizumab for Inflammatory Bowel Disease

60 - 99
All Sexes
Lawrence, MA
This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). These two conditions, known as inflammatory bowel diseases (IBD), cause inflammation (swelling and irritation) in the digestive tract. Older adults with these conditions often have other health issues and face increased risks and complications, making it challenging for them to use certain treatments. Mirikizumab is already approved by the FDA for adults with IBD, but there's limited information about how well it works specifically for older adults. This study aims to fill that gap by seeing if Mirikizumab can help these patients safely manage their condition. The study plans to enroll around 150 people from various locations across the United States. Everyone participating will receive Mirikizumab according to the standard, FDA-approved guidelines. The main goal is to see how many participants achieve clinical remission, meaning their symptoms significantly improve or disappear, after 24 weeks of treatment. Researchers will also look at whether this remission lasts up to 48 weeks, how well symptoms are controlled without steroids, how treatment affects indicators of inflammation (such as blood tests), and how the participants feel overall based on their own reports. The safety of Mirikizumab will also be closely monitored throughout the study by regularly checking for any side effects. This study hopes to provide clearer information to help older adults with IBD and their doctors make better treatment decisions, ultimately improving health outcomes and quality of life.
Phase 4
Waitlist Available
Rubix LSEli Lilly and Company
Have you considered Vitamin K1 clinical trials? We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.Go to Trials
Image of Carolina Digestive Diseases- Site Number : 8400013 in Greenville, United States.

SAR441566 for Ulcerative Colitis

18 - 75
All Sexes
Greenville, NC
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Phase 2
Recruiting
Carolina Digestive Diseases- Site Number : 8400013 (+28 Sites)Sanofi
Image of University of Chicago in Chicago, United States.

Therapy De-escalation for Ulcerative Colitis

18 - 75
All Sexes
Chicago, IL
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on endoscopy and biopsies) who continue to take medical therapy to patients with UC who de-escalate (decrease or discontinue) medical therapy. Both treatment strategies are considered within regular medical practice. Researchers want to find out whether remission can be maintained after de-escalation of therapy. Participants will be: * either be randomly assigned to continue medical therapy or de-escalate medical therapy -OR- be assigned per the participant's preference * clinically managed according to regular medical care * asked to provide blood, stool (poop), and tissue samples for study purposes
Recruiting
Has No Placebo
University of ChicagoDavid T Rubin, MD
Image of University of Pennsylvania in Philadelphia, United States.

Self-Help Interventions for Crohn's Disease

18+
All Sexes
Philadelphia, PA
EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability. This multisite, randomized controlled trial with 16 arms will randomize adults with moderate-to-severe IBD-related disability to a combination of four multimodal behavioral interventions to test their clinical effectiveness in reducing IBD-related disability and improving self-efficacy. The interventions are four existing, publicly available disease-specific self-help resources offered at no cost to the participants: a book, smart app, help center, and peer mentor. Participants will complete online surveys and may engage in virtual focus groups. Participants may receive an honorarium (e-gift card) and/or be entered into a lottery for a giftcards post-survey completion and focus group participation.
Waitlist Available
Has No Placebo
University of Pennsylvania
Have you considered Vitamin K1 clinical trials? We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.Go to Trials
Have you considered Vitamin K1 clinical trials? We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security